Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

UK Company Starts Trials of Inhaled Formulation for COVID-19

Defects on the glass surface are a major cause of occasional breakage of the primary packaging container during fill and finish or transport.

Following reports that hydroxychloroquine and chloroquine are under evaluation in clinical trials as a potential treatment of COVID-19, drug companies are donating doses and planning for ramping up supply.

FDA, EMA Collaborate on SARS-CoV-2 Vaccine Development

On March 23, 2020, Eli Lilly and Company provided an update on the company's clinical trial activities in light of the COVID-19 pandemic.

BioMérieux said on Tuesday that an assay developed by its subsidiary BioFire Defense to rapidly detect COVID-19

Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx

The US Food and Drug Administration on Friday warned consumers to watch out for companies marketing unproven products for diagnosing, preventing, or treating COVID-19.

While many in the US and Europe have only recently come to understand the scope and severity of the SARS-CoV-2 pandemic, a handful of proteomics labs have been studying the virus since the beginning of the year.

A new UK-based research consortium is betting that sequencing the virus that causes COVID-19 can provide policymakers with a clearer picture of the spread of the epidemic across the country as diagnostic testing remains limited.

In a new study published in Nature on Wednesday, researchers in China described the cell type composition of all major human organs, based on the RNA sequences of more than 500,000 single cells from Chinese Han donors.

Personalis reported after the close of the market on Wednesday that its fourth quarter revenues rose 38 percent year over year

Oncocyte said after the close of the market on Wednesday that its fourth quarter net loss rose 77 percent year over year as it pushed toward a transition to commercial test operations.

Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.